- [PRESSWIRE] London, UK – 17.11.23 — Cannatrona, a specialist in the design and manufacture of advanced filter tips and mouthpieces for the cannabis and hemp sectors, will make its debut at MJBizCon 2023 and introduce its new products at booth 1827 from 28 November to 1 December 2023.
- [PRESSWIRE] London, UK – 18th October, 2023 — Veg Power, the not-for-profit alliance to increase the UK’s vegetable consumption, launched its second ground-breaking public health campaign ‘Simply Veg’ today.
- [PRESSWIRE] Switzerland – 31.08.23 — greenteg’s CALERA® technology provides temperature tracking in new generation hybrid, health-monitoring wristwatch.
- [PRESSWIRE] Vienna, Austria – 02.05.2003 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 13, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.
- [PRESSWIRE] Aylesbury – 19 January, 2023 — The New Foscote Hospital Limited announced today that it has completed the acquisition of The Royal Buckinghamshire Hospital, Aylesbury.
- [PRESSWIRE] Aylesbury – 19 January, 2023 — The New Foscote Hospital Limited announced today that it has completed the acquisition of The Royal Buckinghamshire Hospital, Aylesbury.
- [PRESSWIRE] VANCOUVER, BRITISH COLUMBIA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL / Executive Business Services / January 12, 2023 – Atlas Global Brands Inc. (CSE: ATL), (formerly Silver Phoenix Resources Inc. “Silver Phoenix”) (CSE: SP), a global cannabis company with expertise across the cannabis value chain, announces that it has entered into a binding letter of intent (“LOI”) pursuant to which the Company will acquire all of the outstanding securities of a privately-owned licensed cannabis producer (the “Licensed Producer”), based in Ontario with facilities and cultivation processes that are GACP and CUMCS certified to add an additional 3,500 KGs in annual production capacity (the “Proposed Transaction”).
- [PRESSWIRE] VANCOUVER, BRITISH COLUMBIA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL / Executive Business Services / January 12, 2023 – Atlas Global Brands Inc. (CSE: ATL), (formerly Silver Phoenix Resources Inc. “Silver Phoenix”) (CSE: SP), a global cannabis company with expertise across the cannabis value chain, announces that it has entered into a binding letter of intent (“LOI”) pursuant to which the Company will acquire all of the outstanding securities of a privately-owned licensed cannabis producer (the “Licensed Producer”), based in Ontario with facilities and cultivation processes that are GACP and CUMCS certified to add an additional 3,500 KGs in annual production capacity (the “Proposed Transaction”).
- [PRESSWIRE] Nairobi – November 9, 2022 — The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.
- [PRESSWIRE] Nairobi – November 9, 2022 — The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.
- [PRESSWIRE] CO, USA – 07.10.22 — On October 12, St. Moritz celebrates its grand opening in Centennial, Colorado. St. Moritz plans to operate 100 massage schools across the country and the first location is in the Denver Metro area.
- [PRESSWIRE] CO, USA – 07.10.22 — On October 12, St. Moritz celebrates its grand opening in Centennial, Colorado. St. Moritz plans to operate 100 massage schools across the country and the first location is in the Denver Metro area.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 — ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that, to meet the criteria to list its common shares on the Nasdaq Capital Market (“NASDAQ”), the Board of Directors has approved a 1-for-60 reverse share split (the “Reverse Split”), of the Company’s issued and outstanding common shares.
- [PRESSWIRE] London, UK – 16 June, 2022 — Just in time for the summer season, we have the pleasure of welcoming a long-awaited addition to our range: Hello Sunday!
- [PRESSWIRE] London, UK – 13 June 2022 — Datar Cancer Genetics has announced its partnership with U.K. based The Cancer Screening Trust to offer its innovative, blood-based, cancer screening Trucheck solution. Datar Cancer Genetics has been at the forefront in developing greater insight into the cancer ecosystem and offering its innovative oncology focussed services to clinicians and patients globally.
- [PRESSWIRE] EDMOND, OKLAHOMA – MAY 24, 2022 — IRIS JUNE / Soon after Kosmik Brands launched in the great state of Nevada, they are back with more exciting news. Planet 13, globally recognized as the largest cannabis dispensary in the world, now carries all Kosmik products. Setting the world record with their opening back in 2018, since day one, Planet 13 continues to set the bar higher than any other facility when it comes to customer experience. Here’s what’s in store.
- [PRESSWIRE] Asia – 03.05.22 — In South Korea, in cooperation with Heavenly Culture, World Peace and Restoration of Light (HWPL), 18,000 members of Shincheonji Church of Jesus and HWPL participated in blood donation for two weeks from April 18th. This number was recorded as the largest group blood donation in the country.
- [PRESSWIRE] LUBBOCK, TX — April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.
- Sustainable, Ultra-Quiet, German-Engineered Air Purifier Is Designed to Save Lives, Protect the Planet
- [PRESSWIRE] Vienna – 23rd February 2022 — Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).
- [PRESSWIRE] VANCOUVER, BC – January 28th, 2022 — Fobi AI Inc. (FOBI: TSXV; FOBIF: OTCQB) (the “Company” or “FOBI”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is pleased to announce the signing of a deal on January 17th to provide Abbot’s Butcher, a premium plant-based protein brand, with Fobi’s Qples coupon platform.
- • Rapid molecular PCR-like accurate saliva-based test delivers 95% sensitivity and 98% specificity in symptomatic and asymptomatic individuals with SARS-CoV-2 including variants • Designed for point-of-care (POC) diagnosis, ease of use, rapid and cost-effective mass-screening • A mobile-enabled, multiplex platform and connected solution enables efficient real-time reporting of results, track & trace, and surveillance
- [PRESSWIRE] London, UK – 19 January, 2022 — bonebalance™ is a 100% natural food supplement approved for the dietary management of osteoporosis and osteopenia comprising high-quality specific Bioactive Collagen Peptides® that are clinically proven to help form bone matrix – the tissue that gives bones tensile strength and flexibility.
- [PRESSWIRE] London, UK – 14.01.22 — Marodyne LiV is a safe and effective tool for the prevention of osteoporosis and improvement of bone health.
- [PRESSWIRE] Geneva/Zürich, January 11, 2022 – Today marks the launch of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI), a global coalition working to promote and secure a rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances. Psilocybin is the active constituent in what are commonly known as ‘magic mushrooms’, a naturally occurring chemical compound that is increasingly seen as highly safe and effective in treating many forms of mental illness and substance use disorder.
- [PRESSWIRE] VANCOUVER, BC – Dec. 14, 2021 — Fobi AI Inc. Inc. (FOBI:TSXV FOBIF:OTCQB) (the “Company” or “Fobi”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is pleased to announce that Fobi has worked with Kai Medical to help power a rapid Covid testing system for the Galaverse event that was held December 11-13 at the Aria Resort and Casino in Las Vegas by Gala Games. Fobi earned revenue from this project through a development consulting agreement with Kai Medical.
- [PRESSWIRE] London, UK – 30.11.21 — According to the UK’s National Health Service (NHS), the total number of antidepressant prescriptions dispensed during COVID-19 pandemic (January to December 2020) were 78 million, 4 million more than in 2019.
